Due for a bounce?, page-6

From today's announcement:

The first two such clinical studies, which examine physician acceptance and usage of the Quarterly Activities Report for the quarter ended 30 September 2016 3 BREVAGenplus test, commenced in Q4 FY16 with completion expected before the end of Q2 FY17. A third longer-term clinical study that will be prospective in design, examining patient outcomes, is expected to commence within the Q3 FY17 timeframe.

Someone give this company a 101 in shareholder communication. A delay of 2 quarters is nothing out of the ordinary but to be completely silent about it until 6 months later is just ridiculous. Perhaps a kick up the backside at the AGM is required.